Skip to search formSkip to main contentSkip to account menu

bromotetrandrine

Known as: W198 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Objective:  To investigate the safety and pharmacokinetics of bromotetrandrine (BrTet, W198), a novel inhibitor of P‐glycoprotein… 
2009
2009
BACKGROUND Our previous studies have shown that tetrandrine (Tet) reverses the effect of P-glycoprotein (P-gp)-mediated multidrug… 
2009
2009
A rapid and sensitive liquid chromatography-tandem mass spectrometric method (LC-MS/MS) for the determination of bromotetrandrine… 
2007
2007
Objective: The present study aimed to evaluate the MDR reversal activity of bromotetrandrine (BrTet), a bromized derivative of… 
2005
2005
AIM To study the tissue distribution and excretion of bromotetrandrine (W198) in rats. METHODS The concentrations of W198 in… 
2004
2004
Aim To study the pharmacokinetics after combination of bromotetrandrine (W198) with adriamycin in rats. Methods Two HPLC methods… 
2004
2004
AIM To study the pharmacokinetics of bromotetrandrine (W198) in rats and beagle dogs. METHODS The concentrations of W198 in… 
2004
2004
AIM: To study the toxicokinetics after single or combination administration of bromotetrandrine (W198) and adriamycin in beagle… 
2003
2003
Protein kinases phosphorylate a variety of protein substrates in the eukaryotic cell and exhibit different modes of activation…